Can Sangamo Therapeutics Reach Profitability by 2027?

Market analysts are pointing to a potential inflection point for Sangamo Therapeutics, with consensus estimates suggesting the biotech firm could cross into profitability as soon as 2027. This forecast hinges on the company’s ability to successfully commercialize key assets in its development pipeline within a demanding timeframe.

The company’s recent financials paint a challenging picture. Over the past twelve months, Sangamo reported a loss of approximately $109 million, accompanied by a revenue decline of around 37%. A notable positive on the balance sheet, however, is the absence of debt, providing the company with more flexibility than many of its leveraged peers.

According to updated models from four leading analysts, 2026 is Read more...